Moray Campbell

Image
Moray Campbell

Moray Campbell, PhD

Title
Associate Professor
Unit / Department / Division
Pharmaceutics and Pharmacology
Email Address
Phone Number

Professional Interests

Professional Interests

My research goal is to define epigenomic mechanisms that are cancer drivers, and exploit this understanding in diagnostic settings and targeted therapies. Specifically, we focus on understanding how epigenomic events disrupt transcription in solid tumors, notably prostate and breast cancer. To achieve this research goal my group undertakes interdisciplinary approaches. Thus we aim to conceive, design, and interpret experiments that are undertaken both in the wet lab, in Eppendorf tubes, and in the dry lab, at the computer command line.

Education

  • 2016, MS in Bioinformatics, Johns Hopkins University
  • 1994, PhD, Microbiology, University of Kent
  • 1990, BSc, Applied and Industrial Biology, London South Bank University

Honors

  • Dean’s Innovative Research Award, 2019
  • Clinical Sciences Translational Research Fellow, 2011
  • Royal Society Travel Award, 2001
  • Gillard Exchange Fellowship, 2000
  • Pfizer Travel Award, 2000
  • Leukemia Research Fund Wilsede Scholarship, 1998
  • Young Investigator Award, 1997
  • Faculty Degree Prize, 1990

Journal Articles

Sharif GM, Campbell MJ, Nasir A, Sengupta S, Graham GT, Kushner MH, Kietzman WB, Schmidt MO, Pearson GW, Loudig O, Fineberg S, Wellstein A, Riegel AT. An AIB1 isoform alters enhancer access and enables progression of early stage triple-negative breast cancer. Cancer Res. 2021 Jun 16:canres.3625.2020. doi: 10.1158/0008-5472.CAN-20-3625. Epub ahead of print. PMID: 34135000.

Helms TH, Mullins RD, Thomas-Ahner JM, Kulp SK, Campbell MJ, Lucas F, Schmidt N, LeMoine DM, Getaneh S, Xie Z, Phelps MA, Clinton SK, Coss CC. Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks. Sci Rep. 2021 Feb 11;11(1):3646. doi: 10.1038/s41598-021-82252-x. PMID: 33574348; PMCID: PMC7878907.

Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):e2020168118. doi: 10.1073/pnas.2020168118. PMID: 33495337; PMCID: PMC7865186.

Weadick B, Nayak D, Persaud AK, Hung SW, Raj R, Campbell MJ, Chen W, Li J, Williams TM, Govindarajan R. EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1. Mol Cancer Ther. 2021 Feb;20(2):410-422. doi: 10.1158/1535-7163.MCT-20-0316. Epub 2020 Dec 9. PMID: 33298588.

Gray JS, Campbell MJ. Challenges and Opportunities of Genomic Approaches in Therapeutics Development. Methods Mol Biol. 2021;2194:107-126. doi: 10.1007/978-1-0716-0849-4_7. PMID: 32926364.

Siddappa M, Wani SA, Long MD, Leach DA, Mathé EA, Bevan CL, Campbell MJ. Identification of transcription factor co-regulators that drive prostate cancer progression. Sci Rep. 2020 Nov 23;10(1):20332. doi: 10.1038/s41598-020-77055-5. PMID: 33230156; PMCID: PMC7683598.

Kim JY, Bai Y, Jayne LA, Hector RD, Persaud AK, Ong SS, Rojesh S, Raj R, Feng MJHH, Chung S, Cianciolo RE, Christman JW, Campbell MJ, Gardner DS, Baker SD, Sparreboom A, Govindarajan R, Singh H, Chen T, Poi M, Susztak K, Cobb SR, Pabla NS. A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury. Nat Commun. 2020 Apr 21;11(1):1924. doi: 10.1038/s41467-020-15638-6. PMID: 32317630; PMCID: PMC7174303.

Liva SG, Tseng YC, Dauki AM, Sovic MG, Vu T, Henderson SE, Kuo YC, Benedict JA, Zhang X, Remaily BC, Kulp SK, Campbell M, Bekaii-Saab T, Phelps MA, Chen CS, Coss CC. Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. EMBO Mol Med. 2020 Feb 7;12(2):e9910. doi: 10.15252/emmm.201809910. Epub 2020 Jan 13. PMID: 31930715; PMCID: PMC7005646.

Fletcher A, Read ML, Thornton CEM, Larner DP, Poole VL, Brookes K, Nieto HR, Alshahrani M, Thompson RJ, Lavery GG, Landa I, Fagin JA, Campbell MJ, Boelaert K, Turnell AS, Smith VE, McCabe CJ. Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake. Cancer Res. 2020 Jan 1;80(1):102-115. doi: 10.1158/0008-5472.CAN-19-1957. Epub 2019 Oct 31. PMID: 31672844; PMCID: PMC7470018.

Campbell MJ. Tales from topographic oceans: topologically associated domains and cancer. Endocr Relat Cancer. 2019 Nov;26(11):R611-R626. doi: 10.1530/ERC-19-0348. PMID: 31505466; PMCID: PMC7664306.